MedPageToday Pemivibart may have reduced activity against growing variant KP.3.1.1, agency warns. Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.
The agency revised the emergency use authorization (EUA) for the long-acting monoclonal antibody based on available information about SARS-CoV-2 variant susceptibility to pemivibart and national variant frequency, Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, wrote in a letter to pemivibart’s manufacturer, Invivyd
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.